Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BCTXFNYSEAMERICAN:NTNNASDAQ:PBMNYSE:PTN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTXFBriaCell Therapeutics$2.92-2.7%$3.98$3.25▼$17.50$2.25M1.091,859 shs180,001 shsNTNNTN Buzztime$0.22+4.3%$0.21$0.94▼$7.76$652K0.721.63 million shs345,437 shsPBMPsyence Biomedical$5.20+17.6%$4.36$2.92▼$699.19$2.96M-0.1196,967 shs167,734 shsPTNPalatin Technologies$0.09-44.6%$0.00$0.09▼$2.48$2.45M0.942.28 million shs14.57 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTXFBriaCell Therapeutics-2.67%-8.18%-22.13%-32.87%+38.39%NTNNTN Buzztime0.00%+5.80%+9.34%-88.59%-88.59%PBMPsyence Biomedical+17.65%+37.93%+40.37%-53.23%-98.98%PTNPalatin Technologies0.00%0.00%+9,409,900.00%+9,409,900.00%+9,409,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCTXFBriaCell TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANTNNTN BuzztimeN/AN/AN/AN/AN/AN/AN/AN/APBMPsyence BiomedicalN/AN/AN/AN/AN/AN/AN/AN/APTNPalatin TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTXFBriaCell Therapeutics 0.00N/AN/AN/ANTNNTN Buzztime 0.00N/AN/AN/APBMPsyence Biomedical 0.00N/AN/AN/APTNPalatin Technologies 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTXFBriaCell TherapeuticsN/AN/AN/AN/A($4.55) per shareN/ANTNNTN Buzztime$19.81M0.03$0.05 per share4.38$1.76 per share0.12PBMPsyence BiomedicalN/AN/AN/AN/A($61.61) per shareN/APTNPalatin Technologies$350K6.99N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTXFBriaCell Therapeutics-$3.68M-$3.84N/A∞N/AN/AN/A-786.77%N/ANTNNTN Buzztime-$2.05MN/AN/A∞N/A-61.42%-162.54%-49.94%N/APBMPsyence Biomedical-$51.16MN/A0.00∞N/AN/AN/AN/AN/APTNPalatin TechnologiesN/A-$1.55N/A∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTXFBriaCell TherapeuticsN/AN/AN/AN/AN/ANTNNTN BuzztimeN/AN/AN/AN/AN/APBMPsyence BiomedicalN/AN/AN/AN/AN/APTNPalatin TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTXFBriaCell TherapeuticsN/A0.070.07NTNNTN Buzztime3.300.950.95PBMPsyence BiomedicalN/A0.640.64PTNPalatin TechnologiesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTXFBriaCell Therapeutics0.10%NTNNTN Buzztime6.31%PBMPsyence Biomedical77.44%PTNPalatin Technologies11.50%Insider OwnershipCompanyInsider OwnershipBCTXFBriaCell TherapeuticsN/ANTNNTN Buzztime24.20%PBMPsyence Biomedical3.60%PTNPalatin Technologies7.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTXFBriaCell Therapeutics8772,000N/ANot OptionableNTNNTN Buzztime192.98 millionN/ANot OptionablePBMPsyence BiomedicalN/A570,0006.36 millionN/APTNPalatin Technologies3026.01 millionN/AN/ANTN, PTN, BCTXF, and PBM HeadlinesRecent News About These CompaniesPalatin Technologies, Inc. (PTN) Q3 2025 Earnings Call TranscriptMay 15 at 7:02 PM | seekingalpha.comPalatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ...May 15 at 2:39 AM | gurufocus.comQ3 2025 Palatin Technologies Inc Earnings Call TranscriptMay 15 at 12:18 AM | gurufocus.comPalatin Technologies (NYSE:PTN) Now Covered by StockNews.comMay 13, 2025 | americanbankingnews.comFinancial Comparison: Palatin Technologies (NYSE:PTN) & Nature's Sunshine Products (NASDAQ:NATR)May 11, 2025 | americanbankingnews.comPalatin Expects $11.5 Mln Offering To Aid NYSE Compliance And Fuel Obesity Drug DevelopmentMay 9, 2025 | nasdaq.comPalatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025May 9, 2025 | prnewswire.comPalatin Technologies Announces Encouraging Pre-Clinical Data Of PL9588 For Glaucoma TreatmentMay 7, 2025 | nasdaq.comPalatin Technologies faces delisting from NYSE American due to low stock priceMay 7, 2025 | in.investing.comPalatin Technologies faces delisting from NYSE American due to low stock priceMay 7, 2025 | in.investing.comNYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)May 7, 2025 | businesswire.comPalatin Expects $11.5 Million Financing to Cure NYSE American Delisting NoticeMay 7, 2025 | prnewswire.comPalatin Technologies Announces Pricing of up to $23 Million Public OfferingMay 7, 2025 | prnewswire.comPalatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma TherapyMay 5, 2025 | prnewswire.comPL9643 shows promise in dry eye disease treatmentApril 30, 2025 | investing.comPalatin Reports Positive Results From Responder Analyses Of Phase 3 MELODY-1 Study In DEDApril 30, 2025 | nasdaq.comPalatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye DiseaseApril 29, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNTN, PTN, BCTXF, and PBM Company DescriptionsBriaCell Therapeutics OTCMKTS:BCTXF$2.92 -0.08 (-2.67%) As of 05/15/2025BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.NTN Buzztime NYSEAMERICAN:NTN$0.22 +0.01 (+4.29%) As of 05/13/2025NTN Buzztime, Inc., together with its subsidiaries, provides interactive entertainment and technology to bars, restaurants, casinos, and senior living centers in the United States and Canada. Its principal product and service is its tablet platform. The company also leases equipment, including tablets, and cases and charging trays for the tablets to various network subscribers. It also licenses its content to customers to be installed on equipment that they obtain from other parties. The company's interactive entertainment system offers trivia, card, sports, and arcade games. It owns various trademarks, including the Buzztime, Playmaker, Mobile Playmaker, and BEOND Powered. As of June 30, 2020, NTN Buzztime, Inc. served 1,219 venues with its interactive entertainment network. The company was formerly known as NTN Communications, Inc. and changed its name to NTN Buzztime, Inc. in 2005. NTN Buzztime, Inc. was founded in 1982 and is based in Carlsbad, California.Psyence Biomedical NASDAQ:PBM$5.20 +0.78 (+17.65%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$5.26 +0.06 (+1.25%) As of 05/16/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.Palatin Technologies NYSE:PTN$0.09 -0.08 (-44.65%) As of 05/7/2025Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades An Acquisition Just Made Dick's the Most Exciting Stock in Retail CRSPR Stock Could Be Ready to Deliver on Its Massive Promise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
